Sugi Predict

Sugi Predict / Compounds / SCHEMBL278299

SCHEMBL278299

SCHEMBL278299

Cc1nc(N)c2ncn(C3O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]3O[Si](C)(C)C(C)(C)C)c2n1

nearest known ligand 0.49

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ RNASEL Q05823 6/20 0.49
▸ DNMT1 P26358 1/20 0.43
▸ DNMT3B Q9UBC3 1/20 0.43
▸ ADORA3 P0DMS8 3/20 0.43
▸ ADORA2A P29274 4/20 0.41
▸ ADORA2B P29275 3/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ HINT1 P49773 1/20 0.41
▸ NT5E P21589 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13403857 1.00 RNASEL (0.49) RNASELDNMT1DNMT3BADORA3ADORA2A
SCHEMBL20724417 0.92 PDE2A (0.46) RNASELDNMT1DNMT3BADORA3ADORA2A
SCHEMBL11910706 0.90 RNASEL (0.48) RNASELDNMT1DNMT3BADORA3ADORA2A
SCHEMBL278666 0.89 ADORA3 (0.51) DNMT1ADORA3ADORA2AADORA2BADORA1
SCHEMBL4757814 0.89 ADORA3 (0.56) ADORA3ADORA2AADORA2BADORA1NT5E
SCHEMBL13403858 0.89 ADORA3 (0.51) DNMT1ADORA3ADORA2AADORA2BADORA1
SCHEMBL6762689 0.86 ADORA1 (0.50) ADORA3ADORA2AADORA2BADORA1
SCHEMBL21859151 0.86 ADORA1 (0.50) ADORA3ADORA2AADORA2BADORA1
SCHEMBL30867101 0.86 ADORA1 (0.50) ADORA3ADORA2AADORA2BADORA1
SCHEMBL21859282 0.86 ADORA1 (0.50) ADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183226-B2 Myocardial perfusion imaging method GILEAD SCIENCES, INC. (US) 2012-05-22 — — US disclosed
US-8133879-B2 Myocardial perfusion imaging methods and compositions GILEAD SCIENCES, INC. (US) 2012-03-13 — — US disclosed
US-20100272645-A1 MYOCARDIAL PERFUSION IMAGING METHOD GILEAD PALO ALTO, INC. 2010-10-28 — — US disclosed
US-20100183503-A1 MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS GILEAD PALO ALTO, INC. 2010-07-22 — — US disclosed
US-7683037-B2 A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; GILEAD PALO ALTO, INC. (US) 2010-03-23 — — US disclosed
US-7553823-B2 C-pyrazole A2A receptor agonists CV THERAPEUTICS, INC. (US) 2009-06-30 — — US disclosed
US-20070207978-A1 C-Pyrazole A2A receptor agonists CV THERAPEUTICS, INC. 2007-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100183503-A1 MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS ADORA2A, ADORA3, ADORA1 RNASEL 1606/4885DNMT1 4559/4885DNMT3B 3990/4885
US-20100272645-A1 MYOCARDIAL PERFUSION IMAGING METHOD ADORA2A, ADORA3, ADORA2B RNASEL 1336/4885DNMT1 4166/4885DNMT3B 3632/4885
US-20070207978-A1 C-Pyrazole A2A receptor agonists ADORA2A, ADORA3, TBXA2R RNASEL 3130/4885DNMT1 4458/4885DNMT3B 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.